PHG · Koninklijke Philips N.V.

Philips delivered a materially improved Q1 2026 performance versus the prior year, marked by 4% comparable sales growth, 40 bps adjusted EBITA margin expansion to 9.0%, and a sharp rebound in free cash flow to EUR 28 million—driven overwhelmingly by the absence of the EUR 1,025 million Respironics-related settlement payment that weighed on Q1 2025. Segment-level results show divergent dynamics: Personal Health led with 9% comparable sales growth and expanded EBITA margin to 15.8%, reflecting strong consumer demand for Sonicare and OneBlade platforms; Diagnosis & Treatment grew 2% with margin up 30 bps to 9.8%, supported by Image Guided Therapy strength; while Connected Care posted 3% growth but saw EBITA margin decline 60 bps to 2.9% under tariff and inflation pressure. Management attributes margin gains to disciplined productivity actions (EUR 126 million in Q1 savings, on track for EUR 1.5 billion through 2028), innovation monetization—including FDA-cleared AI tools SmartHeart and DeviceGuide—and commercial execution across North America and Western Europe. Critically, Philips reiterated its full-year 2026 guidance without revision, affirming confidence in underlying operational momentum despite acknowledged macro uncertainty, and explicitly excluded potential IEEPA tariff refunds and ongoing Respironics legal matters from assumptions. The newly announced EUR 91 million share repurchase—structured as forward contracts with 2028 delivery—signals capital return discipline aligned with long-term financial targets, not near-term liquidity deployment. Investor focus should center on sustained margin progression into H2, execution of the EUR 1.5 billion productivity program, and whether AI-enabled platform adoption continues to drive above-market growth in core MedTech segments.